Search

Your search keyword '"Shah, Jai"' showing total 632 results
Start Over Author "Shah, Jai"
632 results on '"Shah, Jai"'

1. Emergence and dynamics of delusions and hallucinations across stages in early psychosis

Author

Mourgues-Codern, Catalina, Benrimoh, David, Gandhi, Jay, Farina, Emily A., Vin, Raina, Zamorano, Tihare, Parekh, Deven, Malla, Ashok, Joober, Ridha, Lepage, Martin, Iyer, Srividya N., Addington, Jean, Bearden, Carrie E., Cadenhead, Kristin S., Cornblatt, Barbara, Keshavan, Matcheri, Stone, William S., Mathalon, Daniel H., Perkins, Diana O., Walker, Elaine F., Cannon, Tyrone D., Woods, Scott W., Shah, Jai L., and Powers, Albert R.

Subjects
Quantitative Biology - Neurons and Cognition
Abstract

Hallucinations and delusions are often grouped together within the positive symptoms of psychosis. However, recent evidence suggests they may be driven by distinct computational and neural mechanisms. Examining the time course of their emergence may provide insights into the relationship between these underlying mechanisms. Participants from the second (N = 719) and third (N = 699) iterations of the North American Prodrome Longitudinal Study (NAPLS 2 and 3) were assessed for timing of CHR-P-level delusion and hallucination onset. Pre-onset symptom patterns in first-episode psychosis patients (FEP) from the Prevention and Early Intervention Program for Psychosis (PEPP-Montreal; N = 694) were also assessed. Symptom onset was determined at baseline assessment and the evolution of symptom patterns examined over 24 months. In all three samples, participants were more likely to report the onset of delusion-spectrum symptoms prior to hallucination-spectrum symptoms (odds ratios (OR): NAPLS 2 = 4.09; NAPLS 3 = 4.14; PEPP, Z = 7.01, P < 0.001) and to present with only delusions compared to only hallucinations (OR: NAPLS 2 = 5.6; NAPLS 3 = 11.11; PEPP = 42.75). Re-emergence of delusions after remission was also more common than re-emergence of hallucinations (Ps < 0.05), and hallucinations more often resolved first (Ps < 0.001). In both CHR-P samples, ratings of delusional ideation fell with the onset of hallucinations (P = 0.007). Delusions tend to emerge before hallucinations and may play a role in their development. Further work should examine the relationship between the mechanisms driving these symptoms and its utility for diagnosis and treatment.

Published
2024

3. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis.

Author

Wannan, Cassandra, Nelson, Barnaby, Addington, Jean, Allott, Kelly, Anticevic, Alan, Arango, Celso, Baker, Justin, McGorry, Patrick, Mittal, Vijay, Nordentoft, Merete, Nunez, Angela, Pasternak, Ofer, Pearlson, Godfrey, Perez, Jesus, Perkins, Diana, Powers, Albert, Roalf, David, Sabb, Fred, Schiffman, Jason, Shah, Jai, Smesny, Stefan, Spark, Jessica, Stone, William, Strauss, Gregory, Tamayo, Zailyn, Torous, John, Upthegrove, Rachel, Vangel, Mark, Verma, Swapna, Wang, Jijun, Rossum, Inge, Wolf, Daniel, Wolff, Phillip, Wood, Stephen, Yung, Alison, Agurto, Carla, Alvarez-Jimenez, Mario, Amminger, Paul, Armando, Marco, Asgari-Targhi, Ameneh, Cahill, John, Carrión, Ricardo, Castro, Eduardo, Cetin-Karayumak, Suheyla, Mallar Chakravarty, M, Cho, Youngsun, Cotter, David, DAlfonso, Simon, Ennis, Michaela, Fadnavis, Shreyas, Fonteneau, Clara, Gao, Caroline, Gupta, Tina, Gur, Raquel, Gur, Ruben, Hamilton, Holly, Hoftman, Gil, Jacobs, Grace, Jarcho, Johanna, Ji, Jie, Kohler, Christian, Lalousis, Paris, Lavoie, Suzie, Lepage, Martin, Liebenthal, Einat, Mervis, Josh, Murty, Vishnu, Nicholas, Spero, Ning, Lipeng, Penzel, Nora, Poldrack, Russell, Polosecki, Pablo, Pratt, Danielle, Rabin, Rachel, Rahimi Eichi, Habiballah, Rathi, Yogesh, Reichenberg, Avraham, Reinen, Jenna, Rogers, Jack, Ruiz-Yu, Bernalyn, Scott, Isabelle, Seitz-Holland, Johanna, Srihari, Vinod, Srivastava, Agrima, Thompson, Andrew, Turetsky, Bruce, Walsh, Barbara, Whitford, Thomas, Wigman, Johanna, Yao, Beier, Yuen, Hok, Ahmed, Uzair, Byun, Andrew, Chung, Yoonho, Do, Kim, Hendricks, Larry, Huynh, Kevin, Jeffries, Clark, Lane, Erlend, and Langholm, Carsten

Subjects
clinical high risk, consortium, early detection, prediction, prevention, psychosis, Humans, Psychotic Disorders, Schizophrenia, Prospective Studies, Adult, Prodromal Symptoms, Young Adult, International Cooperation, Adolescent, Research Design, Male, Female
Abstract

This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data processing analysis and coordination center, their processes for data harmonization across 43 sites from 13 participating countries (recruitment across North America, Australia, Europe, Asia, and South America), data flow and quality assessment processes, data analyses, and the transfer of data to the National Institute of Mental Health (NIMH) Data Archive (NDA) for use by the research community. In an expected sample of approximately 2000 CHR individuals and 640 matched healthy controls, AMP SCZ will collect clinical, environmental, and cognitive data along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech and facial expression samples, novel measures derived from digital health technologies including smartphone-based daily surveys, and passive sensing as well as actigraphy. The study will investigate a range of clinical outcomes over a 2-year period, including transition to psychosis, remission or persistence of CHR status, attenuated positive symptoms, persistent negative symptoms, mood and anxiety symptoms, and psychosocial functioning. The global reach of AMP SCZ and its harmonized innovative methods promise to catalyze the development of new treatments to address critical unmet clinical and public health needs in CHR individuals.

Published
2024

7. Effects of Anticholinergic Burden on Verbal Memory Performance in First-Episode Psychosis.

Author

Chakravarty, Mallar, Joober, Ridha, Malla, Ashok, Shah, Jai, Lepage, Martin, Belkacem, Agnès, Lavigne, Katie, and Makowski, Carolina

Subjects
anticholinergic burden, first-episode psychosis, verbal memory, Humans, Cholinergic Antagonists, Psychotic Disorders, Cognition, Cognitive Dysfunction, Cognition Disorders, Neuropsychological Tests
Abstract

OBJECTIVES: Antipsychotics are widely used to treat first-episode psychosis but may have an anticholinergic burden, that is, a cumulative effect of medications that block the cholinergic system. Studies suggest that a high anticholinergic burden negatively affects memory in psychosis, where cognitive deficits, particularly those in verbal memory, are a core feature of the disease. The present study sought to replicate this in a large cohort of well-characterized first-episode psychosis patients. We expected that patients in the highest anticholinergic burden group would exhibit the poorest verbal memory compared to those with low anticholinergic burden and healthy controls at baseline (3 months following admission). We further hypothesized that over time, at month 12, patients verbal memory performance would improve but would remain inferior to controls. METHODS: Patients (n  =  311; low anticholinergic burden [n  =  241] and high anticholinergic burden [n  =  70], defined by a Drug Burden Index cut-off of 1) and healthy controls (n  =  128) completed a clinical and neurocognitive battery including parts of the Wechsler Memory Scale at months 3 and 12. RESULTS: Cross-sectionally, using an analysis of variance, patients in the highest anticholinergic burden group had the poorest performance in verbal memory when compared to the other groups at month 3, F(2,430)  =  52.33, P

Published
2023

11. Qualitative study to explore the perspectives and mental health experiences of first episode psychosis patients and their caregivers in North India

Author

Sood, Mamta, Chadda, Rakesh K., Chawla, Nishtha, Shukla, Tulika, Patil, Vaibhav, Ratra, Dhriti, Rajhans, Pallavi, Padmavati, R., Thara, Rangaswamy, Raghavan, Vijaya, Mohan, Mohapradeep, Iyer, Srividya, Shah, Jai, Madan, Jason, Birchwood, Max, Meyer, Caroline, Lilford, RJ, Furtado, Vivek, Currie, Graeme, and Singh, Swaran P.

Published
2024
Full Text
View/download PDF

12. Protocol-based assessment and management of first episode psychosis: Comparison of short and medium-term outcomes in psychopathology, quality of life, functioning and family burden across two sites in India

Author

Chadda, Rakesh K., Sood, Mamta, Chawla, Nishtha, Padmavati, R., Thara, Rangaswamy, Raghavan, Vijaya, Shukla, Tulika, Patil, Vaibhav, Sen, Mahadev Singh, Mohan, Mohapradeep, Iyer, Srividya, Shah, Jai, Madan, Jason, Birchwood, Max, Meyer, Caroline, Lilford, R.J., Furtado, Vivek, Currie, Graeme, and Singh, Swaran P.

Published
2024
Full Text
View/download PDF

13. Effectiveness of a mental health literacy module on stigma related mental health knowledge and behaviour among youth in two educational settings in Chennai, South India: A quasi-experimental study

Author

Raghavan, Vijaya, Chandrasekaran, Sangeetha, Paul, Vimala, Pattabiraman, Ramakrishnan, Mohan, Greeshma, Durairaj, Jothilakshmi, Currie, Graeme, Lilford, Richard, Furtado, Vivek, Madan, Jason, Birchwood, Maximilian, Meyer, Caroline, Sood, Mamta, Chadda, Rakesh, Mohan, Mohapradeep, Shah, Jai, John, Sujit, Padmavati, R., Iyer, Srividya, Thara, R., and Singh, Swaran

Published
2024
Full Text
View/download PDF

14. Towards a youth mental health paradigm: a perspective and roadmap

Author

Uhlhaas, Peter J., Davey, Christopher G., Mehta, Urvakhsh Meherwan, Shah, Jai, Torous, John, Allen, Nicholas B., Avenevoli, Shelli, Bella-Awusah, Tolulope, Chanen, Andrew, Chen, Eric Y. H., Correll, Christoph U., Do, Kim Q., Fisher, Helen L., Frangou, Sophia, Hickie, Ian B., Keshavan, Matcheri S., Konrad, Kerstin, Lee, Francis S., Liu, Cindy H., Luna, Beatriz, McGorry, Patrick D., Meyer-Lindenberg, Andreas, Nordentoft, Merete, Öngür, Dost, Patton, George C., Paus, Tomáš, Reininghaus, Ulrich, Sawa, Akira, Schoenbaum, Michael, Schumann, Gunter, Srihari, Vinod H., Susser, Ezra, Verma, Swapna K., Woo, T. Wilson, Yang, Lawrence H., Yung, Alison R., and Wood, Stephen J.

Published
2023
Full Text
View/download PDF

16. Designing and implementing a physical exercise intervention for people with first episode psychosis using experience-based co-design: A pilot study from Chennai, India

Author

Vijayalakshmi, U., Padmavati, R., Raghavan, Vijaya, Chandrasekaran, Sangeetha, Mohan, Greeshma, Durairaj, Jothilakshmi, Currie, Graeme, Lilford, Richard, Furtado, Vivek, Madan, Jason, Birchwood, Maximilian, Meyer, Caroline, Sood, Mamta, Chadda, Rakesh, Mohan, Mohapradeep, Shah, Jai, John, Sujit, Iyer, Srividya N., Thara, R., and Singh, Swaran

Published
2024
Full Text
View/download PDF

22. Differential Expression of Anomalous Self-Experiences in Spontaneous Speech in Clinical High-Risk and Early-Course Psychosis Quantified by Natural Language Processing

Author

Srivastava, Agrima, Selloni, Alexandria, Bilgrami, Zarina R., Sarac, Cansu, McGowan, Alessia, Cotter, Matthew, Bayer, Johanna, Spark, Jessica, Krcmar, Marija, Formica, Melanie, Gwyther, Kate, Hartmann, Jessica, Ellenberg, Ezra, Polari, Andrea, McGorry, Patrick, Shah, Jai L., Yung, Alison R., Mizrahi, Romina, Corcoran, Cheryl M., Cecchi, Guillermo A., and Nelson, Barnaby

Published
2023
Full Text
View/download PDF

24. Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit.

Author

Woods, Scott W, Bearden, Carrie E, Sabb, Fred W, Stone, William S, Torous, John, Cornblatt, Barbara A, Perkins, Diana O, Cadenhead, Kristin S, Addington, Jean, Powers, Albert R, Mathalon, Daniel H, Calkins, Monica E, Wolf, Daniel H, Corcoran, Cheryl M, Horton, Leslie E, Mittal, Vijay A, Schiffman, Jason, Ellman, Lauren M, Strauss, Gregory P, Mamah, Daniel, Choi, Jimmy, Pearlson, Godfrey D, Shah, Jai L, Fusar-Poli, Paolo, Arango, Celso, Perez, Jesus, Koutsouleris, Nikolaos, Wang, Jijun, Kwon, Jun Soo, Walsh, Barbara C, McGlashan, Thomas H, Hyman, Steven E, Gur, Raquel E, Cannon, Tyrone D, Kane, John M, and Anticevic, Alan

Subjects
Humans, Syndrome, Psychotic Disorders, Social Stigma, Autonomy, Beneficence, Biomarkers, Clinical high risk, Psychosis, Stigma, Clinical Research, Mental Health, Serious Mental Illness, Pediatric Research Initiative, Prevention, Good Health and Well Being, Medical and Health Sciences, Psychology and Cognitive Sciences, Psychiatry
Abstract

BackgroundMalhi et al. in this issue critique the clinical high risk (CHR) syndrome for psychosis.MethodResponse to points of critique.ResultsWe agree that inconsistency in CHR nomenclature should be minimized. We respectfully disagree on other points. In our view: a) individuals with CHR and their families need help, using existing interventions, even though we do not yet fully understand disease mechanisms; b) substantial progress has been made in identification of biomarkers; c) symptoms used to identify CHR are specific to psychotic illnesses; d) CHR diagnosis is not "extremely difficult"; e) the pattern of progression, although heterogenous, is discernible; f) "psychosis-like symptoms" are common but are not used to identify CHR; and g) on the point described as 'the real risk,' CHR diagnosis does not frequently cause harmful stigma.DiscussionMalhi et al.'s arguments do not fairly characterize progress in the CHR field nor efforts to minimize stigma. That said, much work remains in areas of consistent nomenclature, mechanisms of disease, dissecting heterogeneity, and biomarkers. With regard to what the authors term the "real risk" of stigma associated with a CHR "label," however, our view is that avoiding words like "risk" and "psychosis" reinforces the stigma that both they and we mean to oppose. Moreover, patients and their families benefit from being given a term that describes what is happening to them.

Published
2021

37. Personal Recovery Among People at Risk for Developing Serious Mental Health Problems: A Qualitative Systematic Review.

Author

Jordan, Gerald, Bassetto, Stella, DeLuca, Joseph, Dobbs, Matthew F., Florence, Ana, Allemang, Brooke, O'Keeffe, Donal, Basile, Mikaela, Funaro, Melissa C., Davidson, Larry, Ben-David, Shelly, and Shah, Jai

Subjects
MENTAL health services, PEOPLE with mental illness, MEDICAL care, BORDERLINE personality disorder, MENTAL illness
Abstract

Objective: Personal recovery refers to a person's pursuit of a full, meaningful life despite the potentially debilitating impact of a mental illness. An evidence base describing personal recovery among people at risk for developing a mental illness is lacking, limiting the potential for mental health services to support personal recovery. To address this gap, the authors synthesized the extant research describing personal recovery among people at risk for developing a mental illness. Methods: A systematic search of several literature databases (MEDLINE, Embase, APA PsycInfo, Web of Science Core Collection, and Cochrane Library) was conducted to retrieve qualitative and case studies and first-person accounts. The Joanna Briggs Institute guidelines for systematic reviews were followed. Included studies reported on participants at variable risk for developing a schizophrenia spectrum, bipolar, major depressive, or borderline personality disorder. Articles were retrieved through a librarian-assisted search and through use of additional strategies (e.g., expert consultation). Abstracts were screened by the research team, and themes were developed by using thematic synthesis. Results: The 36 included articles were synthesized, and six themes were generated: difficulties and challenges; establishing an understanding of, and finding ways to cope with, one's mental health challenges; reestablishing a sense of agency and personhood; receiving support from people and services, as well as restoring relationships; reestablishing hope, meaning, and purpose; and overcoming stigma and destigmatizing mental illness in others. Conclusions: These findings provide a conceptual foundation that can guide future research on personal recovery and clinical interventions that foster it among people at risk for mental illness. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Enlarged pituitary gland volume: a possible state rather than trait marker of psychotic disorders

Author

Guimond, Synthia, primary, Alftieh, Ahmad, additional, Devenyi, Gabriel A., additional, Mike, Luke, additional, Chakravarty, M. Mallar, additional, Shah, Jai L., additional, Parker, David A., additional, Sweeney, John A., additional, Pearlson, Godfrey, additional, Clementz, Brett A., additional, Tamminga, Carol A., additional, and Keshavan, Matcheri, additional

Published
2024
Full Text
View/download PDF

44. The Lancet PsychiatryCommission on youth mental health

Author

McGorry, Patrick D, Mei, Cristina, Dalal, Naeem, Alvarez-Jimenez, Mario, Blakemore, Sarah-Jayne, Browne, Vivienne, Dooley, Barbara, Hickie, Ian B, Jones, Peter B, McDaid, David, Mihalopoulos, Cathrine, Wood, Stephen J, El Azzouzi, Fatima Azzahra, Fazio, Jessica, Gow, Ella, Hanjabam, Sadam, Hayes, Alan, Morris, Amelia, Pang, Elina, Paramasivam, Keerthana, Quagliato Nogueira, Isabella, Tan, Jimmy, Adelsheim, Steven, Broome, Matthew R, Cannon, Mary, Chanen, Andrew M, Chen, Eric Y H, Danese, Andrea, Davis, Maryann, Ford, Tamsin, Gonsalves, Pattie P, Hamilton, Matthew P, Henderson, Jo, John, Ann, Kay-Lambkin, Frances, Le, Long K-D, Kieling, Christian, Mac Dhonnagáin, Niall, Malla, Ashok, Nieman, Dorien H, Rickwood, Debra, Robinson, Jo, Shah, Jai L, Singh, Swaran, Soosay, Ian, Tee, Karen, Twenge, Jean, Valmaggia, Lucia, van Amelsvoort, Therese, Verma, Swapna, Wilson, Jon, Yung, Alison, Iyer, Srividya N, and Killackey, Eóin

Published
2024
Full Text
View/download PDF

45. Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit

Author

Woods, Scott W., Bearden, Carrie E., Sabb, Fred W., Stone, William S., Torous, John, Cornblatt, Barbara A., Perkins, Diana O., Cadenhead, Kristin S., Addington, Jean, Powers, Albert R., III, Mathalon, Daniel H., Calkins, Monica E., Wolf, Daniel H., Corcoran, Cheryl M., Horton, Leslie E., Mittal, Vijay A., Schiffman, Jason, Ellman, Lauren M., Strauss, Gregory P., Mamah, Daniel, Choi, Jimmy, Pearlson, Godfrey D., Shah, Jai L., Fusar-Poli, Paolo, Arango, Celso, Perez, Jesus, Koutsouleris, Nikolaos, Wang, Jijun, Kwon, Jun Soo, Walsh, Barbara C., McGlashan, Thomas H., Hyman, Steven E., Gur, Raquel E., Cannon, Tyrone D., Kane, John M., and Anticevic, Alan

Published
2021
Full Text
View/download PDF

47. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ):Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

Author

Wannan, Cassandra M.J., Nelson, Barnaby, Addington, Jean, Allott, Kelly, Anticevic, Alan, Arango, Celso, Baker, Justin T., Bearden, Carrie E., Billah, Tashrif, Bouix, Sylvain, Broome, Matthew R., Buccilli, Kate, Cadenhead, Kristin S., Calkins, Monica E., Cannon, Tyrone D., Cecci, Guillermo, Chen, Eric Yu Hai, Cho, Kang Ik K., Choi, Jimmy, Clark, Scott R., Coleman, Michael J., Conus, Philippe, Corcoran, Cheryl M., Cornblatt, Barbara A., Diaz-Caneja, Covadonga M., Dwyer, Dominic, Ebdrup, Bjørn H., Ellman, Lauren M., Fusar-Poli, Paolo, Galindo, Liliana, Gaspar, Pablo A., Gerber, Carla, Glenthøj, Louise Birkedal, Glynn, Robert, Harms, Michael P., Horton, Leslie E., Kahn, René S., Kambeitz, Joseph, Kambeitz-Ilankovic, Lana, Kane, John M., Kapur, Tina, Keshavan, Matcheri S., Kim, Sung Wan, Koutsouleris, Nikolaos, Kubicki, Marek, Kwon, Jun Soo, Langbein, Kerstin, Lewandowski, Kathryn E., Light, Gregory A., Mamah, Daniel, Marcy, Patricia J., Mathalon, Daniel H., McGorry, Patrick D., Mittal, Vijay A., Nordentoft, Merete, Nunez, Angela, Pasternak, Ofer, Pearlson, Godfrey D., Perez, Jesus, Perkins, Diana O., Powers, Albert R., Roalf, David R., Sabb, Fred W., Schiffman, Jason, Shah, Jai L., Smesny, Stefan, Spark, Jessica, Stone, William S., Strauss, Gregory P., Tamayo, Zailyn, Torous, John, Upthegrove, Rachel, Vangel, Mark, Verma, Swapna, Wang, Jijun, Rossum, Inge Winter van, Wolf, Daniel H., Wolff, Phillip, Wood, Stephen J., Yung, Alison R., Agurto, Carla, Alvarez-Jimenez, Mario, Amminger, Paul, Armando, Marco, Asgari-Targhi, Ameneh, Cahill, John, Carrión, Ricardo E., Castro, Eduardo, Cetin-Karayumak, Suheyla, Mallar Chakravarty, M., Cho, Youngsun T., Cotter, David, D'Alfonso, Simon, Ennis, Michaela, Fadnavis, Shreyas, Fonteneau, Clara, Gao, Caroline, Gupta, Tina, Gur, Raquel E., Gur, Ruben C., Hamilton, Holly K., Hoftman, Gil D., Jacobs, Grace R., Jarcho, Johanna, Ji, Jie Lisa, Kohler, Christian G., Lalousis, Paris Alexandros, Lavoie, Suzie, Lepage, Martin, Liebenthal, Einat, Mervis, Josh, Murty, Vishnu, Nicholas, Spero C., Ning, Lipeng, Penzel, Nora, Poldrack, Russell, Polosecki, Pablo, Pratt, Danielle N., Rabin, Rachel, Rahimi Eichi, Habiballah, Rathi, Yogesh, Reichenberg, Avraham, Reinen, Jenna, Rogers, Jack, Ruiz-Yu, Bernalyn, Scott, Isabelle, Seitz-Holland, Johanna, Srihari, Vinod H., Srivastava, Agrima, Thompson, Andrew, Turetsky, Bruce I., Walsh, Barbara C., Whitford, Thomas, Wigman, Johanna T.W., Yao, Beier, Yuen, Hok Pan, Ahmed, Uzair, Byun, Andrew Jin Soo, Chung, Yoonho, Do, Kim, Hendricks, Larry, Huynh, Kevin, Jeffries, Clark, Lane, Erlend, Langholm, Carsten, Lin, Eric, Mantua, Valentina, Santorelli, Gennarina, Ruparel, Kosha, Zoupou, Eirini, Adasme, Tatiana, Addamo, Lauren, Adery, Laura, Ali, Munaza, Auther, Andrea, Aversa, Samantha, Baek, Seon Hwa, Bates, Kelly, Bathery, Alyssa, Bayer, Johanna M.M., Beedham, Rebecca, Bilgrami, Zarina, Birch, Sonia, Bonoldi, Ilaria, Borders, Owen, Borgatti, Renato, Brown, Lisa, Bruna, Alejandro, Carrington, Holly, Castillo-Passi, Rolando I., Chen, Justine, Cheng, Nicholas, Ching, Ann Ee, Clifford, Chloe, Colton, Beau Luke, Contreras, Pamela, Corral, Sebastián, Damiani, Stefano, Done, Monica, Estradé, Andrés, Etuka, Brandon Asika, Formica, Melanie, Furlan, Rachel, Geljic, Mia, Germano, Carmela, Getachew, Ruth, Goncalves, Mathias, Haidar, Anastasia, Hartmann, Jessica, Jo, Anna, John, Omar, Kerins, Sarah, Kerr, Melissa, Kesselring, Irena, Kim, Honey, Kim, Nicholas, Kinney, Kyle, Krcmar, Marija, Kotler, Elana, Lafanechere, Melanie, Lee, Clarice, Llerena, Joshua, Markiewicz, Christopher, Matnejl, Priya, Maturana, Alejandro, Mavambu, Aissata, Mayol-Troncoso, Rocío, McDonnell, Amelia, McGowan, Alessia, McLaughlin, Danielle, McIlhenny, Rebecca, McQueen, Brittany, Mebrahtu, Yohannes, Mensi, Martina, Hui, Christy Lai Ming, Suen, Yi Nam, Wong, Stephanie Ming Yin, Morrell, Neal, Omar, Mariam, Partridge, Alice, Phassouliotis, Christina, Pichiecchio, Anna, Politi, Pierluigi, Porter, Christian, Provenzani, Umberto, Prunier, Nicholas, Raj, Jasmine, Ray, Susan, Rayner, Victoria, Reyes, Manuel, Reynolds, Kate, Rush, Sage, Salinas, Cesar, Shetty, Jashmina, Snowball, Callum, Tod, Sophie, Turra-Fariña, Gabriel, Valle, Daniela, Veale, Simone, Whitson, Sarah, Wickham, Alana, Youn, Sarah, Zamorano, Francisco, Zavaglia, Elissa, Zinberg, Jamie, Woods, Scott W., Shenton, Martha E., Wannan, Cassandra M.J., Nelson, Barnaby, Addington, Jean, Allott, Kelly, Anticevic, Alan, Arango, Celso, Baker, Justin T., Bearden, Carrie E., Billah, Tashrif, Bouix, Sylvain, Broome, Matthew R., Buccilli, Kate, Cadenhead, Kristin S., Calkins, Monica E., Cannon, Tyrone D., Cecci, Guillermo, Chen, Eric Yu Hai, Cho, Kang Ik K., Choi, Jimmy, Clark, Scott R., Coleman, Michael J., Conus, Philippe, Corcoran, Cheryl M., Cornblatt, Barbara A., Diaz-Caneja, Covadonga M., Dwyer, Dominic, Ebdrup, Bjørn H., Ellman, Lauren M., Fusar-Poli, Paolo, Galindo, Liliana, Gaspar, Pablo A., Gerber, Carla, Glenthøj, Louise Birkedal, Glynn, Robert, Harms, Michael P., Horton, Leslie E., Kahn, René S., Kambeitz, Joseph, Kambeitz-Ilankovic, Lana, Kane, John M., Kapur, Tina, Keshavan, Matcheri S., Kim, Sung Wan, Koutsouleris, Nikolaos, Kubicki, Marek, Kwon, Jun Soo, Langbein, Kerstin, Lewandowski, Kathryn E., Light, Gregory A., Mamah, Daniel, Marcy, Patricia J., Mathalon, Daniel H., McGorry, Patrick D., Mittal, Vijay A., Nordentoft, Merete, Nunez, Angela, Pasternak, Ofer, Pearlson, Godfrey D., Perez, Jesus, Perkins, Diana O., Powers, Albert R., Roalf, David R., Sabb, Fred W., Schiffman, Jason, Shah, Jai L., Smesny, Stefan, Spark, Jessica, Stone, William S., Strauss, Gregory P., Tamayo, Zailyn, Torous, John, Upthegrove, Rachel, Vangel, Mark, Verma, Swapna, Wang, Jijun, Rossum, Inge Winter van, Wolf, Daniel H., Wolff, Phillip, Wood, Stephen J., Yung, Alison R., Agurto, Carla, Alvarez-Jimenez, Mario, Amminger, Paul, Armando, Marco, Asgari-Targhi, Ameneh, Cahill, John, Carrión, Ricardo E., Castro, Eduardo, Cetin-Karayumak, Suheyla, Mallar Chakravarty, M., Cho, Youngsun T., Cotter, David, D'Alfonso, Simon, Ennis, Michaela, Fadnavis, Shreyas, Fonteneau, Clara, Gao, Caroline, Gupta, Tina, Gur, Raquel E., Gur, Ruben C., Hamilton, Holly K., Hoftman, Gil D., Jacobs, Grace R., Jarcho, Johanna, Ji, Jie Lisa, Kohler, Christian G., Lalousis, Paris Alexandros, Lavoie, Suzie, Lepage, Martin, Liebenthal, Einat, Mervis, Josh, Murty, Vishnu, Nicholas, Spero C., Ning, Lipeng, Penzel, Nora, Poldrack, Russell, Polosecki, Pablo, Pratt, Danielle N., Rabin, Rachel, Rahimi Eichi, Habiballah, Rathi, Yogesh, Reichenberg, Avraham, Reinen, Jenna, Rogers, Jack, Ruiz-Yu, Bernalyn, Scott, Isabelle, Seitz-Holland, Johanna, Srihari, Vinod H., Srivastava, Agrima, Thompson, Andrew, Turetsky, Bruce I., Walsh, Barbara C., Whitford, Thomas, Wigman, Johanna T.W., Yao, Beier, Yuen, Hok Pan, Ahmed, Uzair, Byun, Andrew Jin Soo, Chung, Yoonho, Do, Kim, Hendricks, Larry, Huynh, Kevin, Jeffries, Clark, Lane, Erlend, Langholm, Carsten, Lin, Eric, Mantua, Valentina, Santorelli, Gennarina, Ruparel, Kosha, Zoupou, Eirini, Adasme, Tatiana, Addamo, Lauren, Adery, Laura, Ali, Munaza, Auther, Andrea, Aversa, Samantha, Baek, Seon Hwa, Bates, Kelly, Bathery, Alyssa, Bayer, Johanna M.M., Beedham, Rebecca, Bilgrami, Zarina, Birch, Sonia, Bonoldi, Ilaria, Borders, Owen, Borgatti, Renato, Brown, Lisa, Bruna, Alejandro, Carrington, Holly, Castillo-Passi, Rolando I., Chen, Justine, Cheng, Nicholas, Ching, Ann Ee, Clifford, Chloe, Colton, Beau Luke, Contreras, Pamela, Corral, Sebastián, Damiani, Stefano, Done, Monica, Estradé, Andrés, Etuka, Brandon Asika, Formica, Melanie, Furlan, Rachel, Geljic, Mia, Germano, Carmela, Getachew, Ruth, Goncalves, Mathias, Haidar, Anastasia, Hartmann, Jessica, Jo, Anna, John, Omar, Kerins, Sarah, Kerr, Melissa, Kesselring, Irena, Kim, Honey, Kim, Nicholas, Kinney, Kyle, Krcmar, Marija, Kotler, Elana, Lafanechere, Melanie, Lee, Clarice, Llerena, Joshua, Markiewicz, Christopher, Matnejl, Priya, Maturana, Alejandro, Mavambu, Aissata, Mayol-Troncoso, Rocío, McDonnell, Amelia, McGowan, Alessia, McLaughlin, Danielle, McIlhenny, Rebecca, McQueen, Brittany, Mebrahtu, Yohannes, Mensi, Martina, Hui, Christy Lai Ming, Suen, Yi Nam, Wong, Stephanie Ming Yin, Morrell, Neal, Omar, Mariam, Partridge, Alice, Phassouliotis, Christina, Pichiecchio, Anna, Politi, Pierluigi, Porter, Christian, Provenzani, Umberto, Prunier, Nicholas, Raj, Jasmine, Ray, Susan, Rayner, Victoria, Reyes, Manuel, Reynolds, Kate, Rush, Sage, Salinas, Cesar, Shetty, Jashmina, Snowball, Callum, Tod, Sophie, Turra-Fariña, Gabriel, Valle, Daniela, Veale, Simone, Whitson, Sarah, Wickham, Alana, Youn, Sarah, Zamorano, Francisco, Zavaglia, Elissa, Zinberg, Jamie, Woods, Scott W., and Shenton, Martha E.

Abstract

This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data processing analysis and coordination center, their processes for data harmonization across 43 sites from 13 participating countries (recruitment across North America, Australia, Europe, Asia, and South America), data flow and quality assessment processes, data analyses, and the transfer of data to the National Institute of Mental Health (NIMH) Data Archive (NDA) for use by the research community. In an expected sample of approximately 2000 CHR individuals and 640 matched healthy controls, AMP SCZ will collect clinical, environmental, and cognitive data along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech and facial expression samples, novel measures derived from digital health technologies including smartphone-based daily surveys, and passive sensing as well as actigraphy. The study will investigate a range of clinical outcomes over a 2-year period, including transition to psychosis, remission or persistence of CHR status, attenuated positive symptoms, persistent negative symptoms, mood and anxiety symptoms, and psychosocial functioning. The global reach of AMP SCZ and its harmonized innovative methods promise to catalyze the development of new treatments to address critical unmet clinical and public health needs in CHR individuals., This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data processing analysis and coordination center, their processes for data harmonization across 43 sites from 13 participating countries (recruitment across North America, Australia, Europe, Asia, and South America), data flow and quality assessment processes, data analyses, and the transfer of data to the National Institute of Mental Health (NIMH) Data Archive (NDA) for use by the research community. In an expected sample of approximately 2000 CHR individuals and 640 matched healthy controls, AMP SCZ will collect clinical, environmental, and cognitive data along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech and facial expression samples, novel measures derived from digital health technologies including smartphone-based daily surveys, and passive sensing as well as actigraphy. The study will investigate a range of clinical outcomes over a 2-year period, including transition to psychosis, remission or persistence of CHR status, attenuated positive symptoms, persistent negative symptoms, mood and anxiety symptoms, and psychosocial functioning. The global reach of AMP SCZ and its harmonized innovative methods promise to catalyze the development of new treatments to address critical unmet clinical and public health needs in CHR individuals.

Published
2024

48. Development of the PSYCHS:Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS

Author

Woods, Scott W., Parker, Sophie, Kerr, Melissa J., Walsh, Barbara C., Wijtenburg, S. Andrea, Prunier, Nicholas, Nunez, Angela R., Buccilli, Kate, Mourgues-Codern, Catalina, Brummitt, Kali, Kinney, Kyle S., Trankler, Carli, Szacilo, Julia, Colton, Beau Luke, Ali, Munaza, Haidar, Anastasia, Billah, Tashrif, Huynh, Kevin, Ahmed, Uzair, Adery, Laura L., Marcy, Patricia J., Allott, Kelly, Amminger, Paul, Arango, Celso, Broome, Matthew R., Cadenhead, Kristin S., Chen, Eric Y. H., Choi, Jimmy, Conus, Philippe, Cornblatt, Barbara A., Glenthøj, Louise Birkedal, Horton, Leslie E., Kambeitz, Joseph, Kapur, Tina, Keshavan, Matcheri S., Koutsouleris, Nikolaos, Langbein, Kerstin, Lavoie, Suzie, Diaz-Caneja, Covadonga Martinez, Mathalon, Daniel H, Mittal, Vijay A., Nordentoft, Merete, Pasternak, Ofer, Pearlson, Godfrey D, Gaspar, Pablo A., Shah, Jai L., Smesny, Stefan, Stone, William S., Strauss, Gregory P., Wang, Jijun, Corcoran, Cheryl M., Perkins, Diana O., Schiffman, Jason, Perez, Jesus, Mamah, Daniel, Ellman, Lauren M., Powers, Albert R., Coleman, Michael J., Anticevic, Alan, Fusar-Poli, Paolo, Kane, John M., Kahn, Rene S., McGorry, Patrick D., Bearden, Carrie E, Shenton, Martha E., Nelson, Barnaby, Calkins, Monica E., Hendricks, Larry, Bouix, Sylvain, Addington, Jean, McGlashan, Thomas H, Yung, Alison R., Woods, Scott W., Parker, Sophie, Kerr, Melissa J., Walsh, Barbara C., Wijtenburg, S. Andrea, Prunier, Nicholas, Nunez, Angela R., Buccilli, Kate, Mourgues-Codern, Catalina, Brummitt, Kali, Kinney, Kyle S., Trankler, Carli, Szacilo, Julia, Colton, Beau Luke, Ali, Munaza, Haidar, Anastasia, Billah, Tashrif, Huynh, Kevin, Ahmed, Uzair, Adery, Laura L., Marcy, Patricia J., Allott, Kelly, Amminger, Paul, Arango, Celso, Broome, Matthew R., Cadenhead, Kristin S., Chen, Eric Y. H., Choi, Jimmy, Conus, Philippe, Cornblatt, Barbara A., Glenthøj, Louise Birkedal, Horton, Leslie E., Kambeitz, Joseph, Kapur, Tina, Keshavan, Matcheri S., Koutsouleris, Nikolaos, Langbein, Kerstin, Lavoie, Suzie, Diaz-Caneja, Covadonga Martinez, Mathalon, Daniel H, Mittal, Vijay A., Nordentoft, Merete, Pasternak, Ofer, Pearlson, Godfrey D, Gaspar, Pablo A., Shah, Jai L., Smesny, Stefan, Stone, William S., Strauss, Gregory P., Wang, Jijun, Corcoran, Cheryl M., Perkins, Diana O., Schiffman, Jason, Perez, Jesus, Mamah, Daniel, Ellman, Lauren M., Powers, Albert R., Coleman, Michael J., Anticevic, Alan, Fusar-Poli, Paolo, Kane, John M., Kahn, Rene S., McGorry, Patrick D., Bearden, Carrie E, Shenton, Martha E., Nelson, Barnaby, Calkins, Monica E., Hendricks, Larry, Bouix, Sylvain, Addington, Jean, McGlashan, Thomas H, and Yung, Alison R.

Abstract

Aim: To harmonize two ascertainment and severity rating instruments commonly used for the clinical high risk syndrome for psychosis (CHR-P): the Structured Interview for Psychosis-risk Syndromes (SIPS) and the Comprehensive Assessment of At-Risk Mental States (CAARMS). Methods: The initial workshop is described in the companion report from Addington et al. After the workshop, lead experts for each instrument continued harmonizing attenuated positive symptoms and criteria for psychosis and CHR-P through an intensive series of joint videoconferences. Results: Full harmonization was achieved for attenuated positive symptom ratings and psychosis criteria, and modest harmonization for CHR-P criteria. The semi-structured interview, named Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS (PSYCHS), generates CHR-P criteria and severity scores for both CAARMS and SIPS. Conclusions: Using the PSYCHS for CHR-P ascertainment, conversion determination, and attenuated positive symptom severity rating will help in comparing findings across studies and in meta-analyses.

Published
2024

49. Combinations and Temporal Associations Among Precursor Symptoms Before a First Episode of Psychosis.

Author

Paquin, Vincent, Malla, Ashok K, Iyer, Srividya N, Lepage, Martin, Joober, Ridha, and Shah, Jai L

Subjects
EARLY medical intervention, RESEARCH funding, INTERVIEWING, SYMPTOMS, RETROSPECTIVE studies, DESCRIPTIVE statistics, RESEARCH methodology, MEDICAL records, ACQUISITION of data, ELECTRONIC health records, PSYCHOSES, CONFIDENCE intervals, DISEASE progression
Abstract

Background and Hypothesis Symptoms that precede a first episode of psychosis (FEP) can ideally be targeted by early intervention services with the aim of preventing or delaying psychosis onset. However, these precursor symptoms emerge in combinations and sequences that do not rest fully within traditional diagnostic categories. To advance our understanding of illness trajectories preceding FEP, we aimed to investigate combinations and temporal associations among precursor symptoms. Study Design Participants were from PEPP-Montréal, a catchment-based early intervention program for FEP. Through semistructured interviews, collateral from relatives, and a review of health and social records, we retrospectively measured the presence or absence of 29 precursor symptoms, including 9 subthreshold psychotic and 20 nonpsychotic symptoms. Sequences of symptoms were derived from the timing of the first precursor symptom relative to the onset of FEP. Study Results The sample included 390 participants (68% men; age range: 14–35 years). Combinations of precursor symptoms most frequently featured depression, anxiety, and substance use. Of 256 possible pairs of initial and subsequent precursor symptoms, many had asymmetrical associations: eg, when the first symptom was suspiciousness, the incidence rate ratio (IRR) of subsequent anxiety was 3.40 (95% confidence interval [CI]: 1.79, 6.46), but when the first symptom was anxiety, the IRR of subsequent suspiciousness was 1.15 (95% CI: 0.77, 1.73). Conclusions A detailed examination of precursor symptoms reveals diverse clinical profiles that cut across diagnostic categories and evolve longitudinally prior to FEP. Their identification may contribute to risk assessments and provide insights into the mechanisms of illness progression. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Examining the psychobiological response to acute social stress across clinical stages and symptom trajectories in the early psychosis continuum.

Author

Shah, Jai L., Paquin, Vincent, McIlwaine, Sarah V., Malla, Ashok K., Joober, Ridha, and Pruessner, Marita

Subjects
*SUBJECTIVE stress, *SYSTOLIC blood pressure, *PSYCHOBIOLOGY, *HEART beat, *BLOOD pressure
Abstract

The stress-vulnerability model has been repeatedly highlighted in relation to the risk, onset and course of psychosis, and has been independently studied in clinical high-risk (CHR) and first-episode psychosis (FEP) populations. Notable in this literature, however, is that there are few studies directly comparing markers of stress response across progressive stages of illness. Here we examined the psychobiological response to the Trier Social Stress Test in 28 CHR (mean age 19.1) and 61 FEP (age 23.0) patients, in order to understand the stage(s) or trajectories in which differences in subjective stress or physiological response occur. The overall clinical sample had greater perceived stress and blunted cortisol (FEP + CHR, n = 89, age 21.7) compared with healthy controls (n = 45, age 22.9). Additional analyses demonstrated elevated heart rate and systolic blood pressure in FEP compared with CHR, but there were no further differences in physiological parameters (cortisol, heart rate, or blood pressure) between stage- or trajectory-based groups. Together, this suggests that individual stress response markers may differentially emerge at particular stages en route to psychosis – and demonstrates how stage-based analyses can shed light on the emergence and evolution of neurobiological changes in mental illness. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results